It provides more information about agomelatine’s role as a potent

It provides more information about agomelatine’s role as a potential adjuvant to other antidepressants and antipsychotics and suggests that agomelatine in combination with other medications is being used routinely in clinical practice. Footnotes This research received no specific grant from any funding agency in the public, trichostatin a clinical trials commercial, or not-for-profit sectors. The authors declare no conflicts

Inhibitors,research,lifescience,medical of interest in preparing this article.
Blockade of the dopamine D2 receptor is a key mechanism in the antipsychotic selleck Wortmannin treatment of patients diagnosed with a psychotic disorder but has also been associated with emotional impairments [Artaloytia et al. 2006; Carlsson, 1988; Van Putten et al. 1981]. Evidence for a negative impact of D2 blockade on emotional experience, however, has been based mainly on results from data collected with medication-related, cross-sectional questionnaires in semi-experimental environments, lacking ecological validity. In a previous study [Lataster Inhibitors,research,lifescience,medical et al. 2010] the association between D2 receptor occupancy and experience of emotions in daily life reality was investigated using the experience sampling method (ESM), a fine-grained Inhibitors,research,lifescience,medical momentary assessment technique for collecting emotional experiences in the flow of daily life [Myin-Germeys et al. 2009; Delespaul, 1995]. Results from this study showed that occupancy of the

D2 receptor, Inhibitors,research,lifescience,medical occasioned by the antipsychotics haloperidol and risperidone, was associated with impaired emotional experience [Lataster et al. 2010]. In the current experiment, the same method was used to investigate the effects of aripiprazole treatment on psychotic symptoms and emotional

Inhibitors,research,lifescience,medical experience in a sample of 13 patients with schizophrenia who were switched from treatment with traditional dopamine antagonist antipsychotics to treatment with the partial dopamine agonist aripiprazole. Aripiprazole has been shown to be adequate in reducing psychotic symptoms [Kim et al. 2009] and may, because of its partial D2 agonistic properties, have preferential effects on the dopaminergic motivation and reward system compared with pure dopamine antagonist antipsychotics, possibly resulting in a different subjectively experienced side-effects profile. Indeed, despite very high levels of D2 occupancy, aripiprazole treatment has been associated with better scores Cilengitide on the Subjective Well-being under Neuroleptics (SWN) scale compared with traditional D2 antagonist antipsychotics [Mizrahi et al. 2009]. The current study aimed at adding ecological validity to these results by monitoring emotional experience and psychotic symptoms in daily life reality. Method Patients The sample consisted of 13 patients with a diagnosis of schizophrenia, displaying insufficient therapeutic response to antipsychotic treatment.

Leave a Reply

Your email address will not be published. Required fields are marked *

*

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>